LMDX News and Press, LumiraDx Limited From 03/21/23

LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022. Full year 2022 revenues of $254.5 million. Q4 2022 reven...

LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21 st , 2023. On the day of the release, LumiraD...

LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7 th , 2023 at 4:35pm ET. Webcast...

LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement under Nasdaq L...

LumiraDx Limited ( NASDAQ: LMDX ) added ~9% pre-market Monday after announcing U.S. and U.K. regulatory clearances for a diagnostic assay that allows the simultaneous detection of COVID-19 and influenza viruses. With the Emergency Use Authorization (EUA) by the FDA and validation ...

LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay receives Emergency Use Authorization from the FDA along with being successfully validated by the UK Health Security Agency (UKHSA) under the Coronavirus Test Device Approvals (CTDA) process. This multiplex test utilizes the in...

LumiraDx ( NASDAQ: LMDX ) said it had received notification from the Nasdaq that it is not in compliance with the minimum bid price  for continued listing as the closing bid price  was below US$1. The Company has a period of 180 calendar days, or until  January 27, ...

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available. The LumiraDx NT-proBNP ...

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasda...

WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced findings from its second annual “Point of Care Diagnostics: A Clinician's View” U.S. survey, designed to understand physicians...